We invited CEO of Simbec-Orion, Fabrice Chartier, and CEO of biotx.ai, Joern Klinger, to discuss how early utilisation of AI could help de-risk and accelerate clinical development, and where drug developers should start when considering adding AI to their clinical development strategy.
Register to discover how the early inclusion of AI-enabled causal modelling can:
- Support your decision-making, and provide additional data to demonstrate efficacy to potential investors, as early as the nonclinical stage
- Identify all causal biomarkers for your target indication so you can better design your early-phase study
- Support indication selection and, in some cases, provide alternative indications to expand your pipeline options
- Provide intelligence that supports highly targeted clinical trial design, optimising budget allocation and potentially accelerating your journey to your goal milestones